Borson-Chazot F, Brue T
Fédération d'Endocrinologie, Groupement hospitalier Lyon-Est, 69677 Bron cedex.
Ann Endocrinol (Paris). 2006 Sep;67(4):303-9. doi: 10.1016/s0003-4266(06)72602-6.
Brain radiotherapy is a frequent and overlooked cause of pituitary deficiency in adults which may alter patients' health and quality of life. Hormonal consequences have been better studied in children. The onset of hormonal deficiencies depends on the dose delivered to the pituitary-hypothalamic region while their incidence and severity depends on dose fractionating and follow-up duration. Somatotrophic function is the first affected, 90% of patients being GH deficient 10 years after radiotherapy. Other anterior pituitary functions are affected later and less frequently. While initial damage occurs in the hypothalamus, accounting for mild hyperprolactinemia in 30-50% of cases, diabetes insipidus is never observed. Direct pituitary deficiency may occur later. Responses to ACTH or GHRH-arginine tests may be normal for several years though an ACTH and/or GH deficiency has been demonstrated by an insulin tolerance test, which is considered as the gold standard. When the cranio-spinal area--including the neck--has been irradiated, primary thyroid deficiency might occur. Repeated cervical ultrasonographic follow-up is mandatory to exclude radiation-induced thyroid cancer. The gonadotrophic function might be altered after small doses of irradiation causing precocious puberty, while at higher doses delayed puberty or true gonadotrophic deficiencies are more often observed. Combined radio- and chemotherapy might result in mixed central and peripheral deficiencies that might be difficult to diagnose. When radiotherapy is performed in adulthood, GH deficiency is less common, although the sequence of hormonal deficiencies is similar to that observed in children. Prospective longitudinal studies are required to determine the time course and sequence of onset of each deficiency, in order to tailor the monitoring of these patients to their specific needs.
脑部放疗是成人垂体功能减退的常见但被忽视的原因,这可能会改变患者的健康状况和生活质量。在儿童中,对激素方面的后果已有更深入的研究。激素缺乏的发生取决于垂体 - 下丘脑区域所接受的剂量,而其发生率和严重程度则取决于剂量分割和随访时间。生长激素功能是首先受到影响的,放疗后10年90%的患者生长激素缺乏。其他垂体前叶功能受到影响的时间较晚且频率较低。虽然最初的损伤发生在下丘脑,30 - 50%的病例会出现轻度高泌乳素血症,但从未观察到尿崩症。直接的垂体功能减退可能在之后出现。尽管胰岛素耐量试验(被视为金标准)已证明存在促肾上腺皮质激素(ACTH)和/或生长激素缺乏,但对ACTH或生长激素释放激素 - 精氨酸试验的反应可能在数年内仍正常。当包括颈部在内的颅脊髓区域受到照射时,可能会发生原发性甲状腺功能减退。必须进行反复的颈部超声随访以排除放射性甲状腺癌。小剂量照射后促性腺激素功能可能会改变,导致性早熟,而在较高剂量时,更常观察到青春期延迟或真正的促性腺激素缺乏。放疗和化疗联合可能导致中枢和外周混合性缺乏,这可能难以诊断。在成年期进行放疗时,生长激素缺乏不太常见,尽管激素缺乏的顺序与儿童中观察到的相似。需要进行前瞻性纵向研究来确定每种缺乏症发生的时间进程和顺序,以便根据这些患者的具体需求调整监测。